Neoolife Inc. Awarded NIH Grant and Reaches Key Development Milestone with Successful 6-month Ovine Data on Biomimetic Polymeric Biodegradable Heart Valve Platform

Neoolife Inc. Awarded NIH Grant and Reaches Key Development Milestone with Successful 6-month Ovine Data on Biomimetic Polymeric Biodegradable Heart Valve Platform

 

[Pittsburgh, PA] – [10 September 2024] Neoolife, Inc., a leading company in biomedical technology and healthcare innovation, is pleased to announce a significant achievement with the successful completion of 6-month ovine studies for its biomimetic polymeric biodegradable heart valve platform. Supported by the prestigious NIH Phase I STTR grant (1R41HL167502-01A1), awarded in April 2023, this advancement highlights the company’s commitment to revolutionizing heart valve therapy by leveraging its innovative biodegradable design and advanced DCD technology to promote endogenous tissue growth.

The positive ovine study results, featuring a biomimetic polymeric biodegradable heart valve in the pulmonary position, mark a critical milestone in Neoolife’s strategic vision. This achievement demonstrates the potential of their cutting-edge heart valve technology and the promising development of their biomimetic polymeric biodegradable pulmonary heart valve platform.

David Kokot, President & CEO of Neoolife, Inc., emphasized the importance of this progress, stating, “This success showcases our team’s relentless pursuit of medical innovation and takes us a step closer to revolutionizing patient treatment.” Antonio D’Amore, CTO, added, “We are excited to reach this critical milestone in our project, thanks to the support from the NIH grant.”

 

Neoolife, Inc. remains committed to its mission of delivering pioneering medical solutions to meet unmet healthcare needs.